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Autosomal dominant polycystic kidney disease (ADPKD) affects 1 in 400 to 1,000 live 
births, making it the most common monogenic cause of renal failure. Although no definite 
cure is available yet, it is important to affect disease progression by influencing modifiable 
factors such as hypertension and proteinuria. Besides this symptomatic management, 
the only drug currently recommended in Europe for selected adult patients with rapid 
disease progression, is the vasopressin receptor antagonist tolvaptan. However, the 
question remains whether these preventive interventions should be initiated before 
extensive renal damage has occurred. As renal cyst formation and expansion begins 
early in life, frequently in utero, ADPKD should no longer be considered an adult-onset 
disease. Moreover, the presence of hypertension and proteinuria in affected children 
has been reported to correlate well with disease severity. Until now, it is controversial 
whether children at-risk for ADPKD should be tested for the presence of the disease, 
and if so, how this should be done. Herein, we review the spectrum of pediatric ADPKD 
and discuss the pro and contra of testing at-risk children and the challenges and unmet 
needs in pediatric ADPKD care.
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AUTOSOMAL DOMiNANT POLYCYSTiC KiDNeY DiSeASe 
(ADPKD) AND iTS SPeCTRUM iN PeDiATRiC PATieNTS
Autosomal dominant polycystic kidney disease affects 1 in 400 to 1,000 live births, making it the 
most common monogenic cause of renal failure and representing a major socio-economic medical 
problem in the world (1). The disorder arises as a consequence of PKD1 or PKD2 gene mutations, 
encoding polycystin-1 (PC1) and -2 (PC2), and accounting for 85 and 15% of patients with a PKD 
gene mutation, respectively. Recently, a third gene has been identified to cause ADPKD when mutated, 
namely GANAB (Glucosidase, Alpha, Neutral AB form), encoding the glucosidase IIa subunit (2). 
Although most cases are familial, in 10–25% of patients, a positive family history is absent, posing 
a diagnostic challenge. These cases are explained by de novo disease in up to 10–15% (3), missing 
parental medical records, germline or somatic mosaicism, or mild disease from hypomorphic PKD1 
and PKD2 mutations (4).
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ADPKD, autosomal dominant polycystic kidney disease; ARB, 
angiotensin receptor blocker; CKD, chronic kidney disease; (e)GFR, (estimated) glomerular filtration rate; LVH, left ventricular 
hypertrophy; MRI, magnetic resonance imaging; RAAS, renin–angiotensin–aldosterone system; TKV, total kidney volume; 
VEO, very early onset; US, ultrasound.
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Autosomal dominant polycystic kidney disease is character-
ized by a progressive growth of cysts in all nephron segments, 
ultimately leading to end-stage renal disease (ESRD) in 50% of 
patients in the sixth decade. ADPKD patients with a PKD2 muta-
tion have a milder phenotype and reach ESRD approximately 
20 years later than PKD1 patients. Within the PKD1 population, 
patients with a truncating mutation are more severely affected 
than those with a non-truncating. Therefore, PKD gene mutation 
analysis is one of the elements forming the PROPKD scoring 
system, an algorithm to predict renal survival in adult ADPKD 
patients (5). Moreover, ADPKD as a bona fide ciliopathy is a 
systemic disorder, comprising extrarenal symptoms such as cyst 
formation in other organs, mostly in the liver, hypertension, 
intracranial arterial aneurysms, cardiac valvular defects, inguinal 
and abdominal herniation, etc. (6). Recently, there is also evidence 
of bone and mineral metabolism anomalies, from both studies in 
different animal ADPKD models (7–9) as from clinical studies in 
adult and pediatric patients (7, 10–14).
As the majority of patients remain a- or pauci-symptomatic 
until adulthood, ADPKD is still often considered as a late-onset 
disease (15). Historically, ADPKD was termed “adult” polycystic 
kidney disease due to this classic presentation (16). However, 
comorbidities might be underdiagnosed in childhood if not 
actively looked for by caregivers as not all cause complaints. 
Moreover, the glomerular filtration rate (GFR) masks the 
underlying renal damage for several decades, due to hyperfiltra-
tion and hypertrophy of unaffected residual nephrons (17). The 
parameter proven to be a strong and independent predictor for 
ESRD development in ADPDK patients was the factual anatomic 
damage, indirectly assessed as the height-adjusted total kidney 
volume (TKV) on magnetic resonance imaging (MRI) (18, 19). 
Although evidence is growing that renal injury starts with the 
formation of the first renal cysts in utero (20), a consensus for the 
management of children at-risk for or diagnosed with ADPKD is 
lacking. Indeed, of all ADPKD patients, 2–5% present in child-
hood with a broad phenotypic spectrum, ranging from severe 
neonatal presentations mimicking autosomal recessive polycystic 
kidney disease (21) to the incidental sonographic finding of renal 
cysts (22). Here, we aimed to summarize the most important 
manifestations of ADPKD in childhood.
Renal Manifestations in Childhood
Possible presenting symptoms of renal disease in children with 
ADPKD are frequency, nocturia and/or, hematuria, urinary tract 
infection(s) and back, flank or abdominal pain (23). Often, the 
earliest biological renal manifestation of childhood ADPKD is a 
decreased urinary concentrating ability, resulting in polyuria and 
polydipsia (15). 58% of children (N = 53) showed a decreased renal 
concentrating capacity when performing a standardized renal 
concentrating capacity test after nasal drop application of desmo-
pressin (24). In several study cohorts, children were included 
having a decreased estimated GFR (eGFR): 12 (25) to 39% (26) of 
the ADPKD children had eGFR levels < 90 mL/min/1.73 m2, and 
ESRD was seldom observed. Indeed, cases of ESRD in childhood 
due to ADPKD are rare and in these cases, coexisting reasons for 
renal function decline should be ruled out. Other reasons might 
be the coinheritance of a hypomorphic PKD1 allele in trans with 
an inactivating PKD1 allele or the inheritance of two incom-
pletely penetrant PKD1 alleles—most likely leading to very early 
onset (VEO) ADPKD (27, 28). Children with ADPKD display 
glomerular hyperfiltration in 18 (29) to 21% (25). Importantly, 
the occurrence of hyperfiltration was associated with a signifi-
cantly faster renal function impairment and a higher renal growth 
rate over time (29). Also, proteinuria and microalbuminuria are 
seen in ADPKD, and more frequently in children and adolescents 
than in adults. In different pediatric cohorts, the prevalence of 
micro-albuminuria and proteinuria ranges from 30 to 48% and 
10 to 23%, respectively (25, 26, 30). From studies performed in 
both pediatric (30) and adult (31) patient cohorts, it was shown 
that patients with established proteinuria have a more aggressive 
course of renal disease. Indeed, adult proteinuric patients had 
higher mean arterial pressures, larger renal volumes and lower 
creatinine clearances compared to the non-proteinuric subjects 
(31). Similarly, proteinuric children had a more severe renal 
disease -defined as having more than 10 renal cysts—then those 
without proteinuria. However, unlike in adults, no correlation 
between proteinuria and hypertension, one of the most prevalent 
extrarenal manifestations, was seen in children (30). Last, hema-
turia, both possible after an antecedent of abdominal trauma, 
for instance in patients playing contact sports, as spontaneously 
(32), and nephrolithiasis are rather uncommon in children (15). 
A prevalence of the latter is lacking, as information comes from 
case reports (33). Moreover, nephrolithiasis is seen in up to 28% 
of ADPKD patients, which is 5–10 times the rate in the general 
population, due to both anatomic and metabolic abnormalities; 
but none in the patients below 20  years of age (34). Different 
from the general population is that nephrolithiasis in ADPKD 
patients should only be made after ruling out a superimposed 
urinary tract infection, cyst infection or hemorrhage and that 
screening for underlying urinary metabolic abnormalities should 
be performed from the first presentation (35).
The anatomic renal damage can often already be seen from a 
young age as renal cysts and/or uni- or bilateral nephromegaly. In 
a cohort of 47 ADPKD children, all had accelerated renal growth 
relative to the normal population, and half had nephromegaly 
(26). Affected individuals who do not yet have cysts detectable by 
ultrasound (US) were shown to have larger age-adjusted kidneys, 
suggesting ongoing microscopic cyst development and growth 
(36). Importantly, mathematical models computing volume 
changes of solitary and multiple cysts in function of time show 
that cysts formed early in life, are the main contributors to the 
final total cyst volume (37).
Another major symptom of childhood ADPKD, explained 
by anomalies in both the renal and cardiovascular system, 
namely hypertension, will be discussed in Section “Extrarenal 
Manifestations in Childhood: Cardiovascular Symptoms.”
extrarenal Manifestations in Childhood: 
Cardiovascular Symptoms
Cardiovascular manifestations are the most prominent extrarenal 
manifestation in ADPKD, also in childhood, of which hyperten-
sion occurs in a majority of patients, prior to renal function 
decline. The reported incidence in childhood varies widely in 
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different cohorts, namely from 5 to 44% (15): 6% (25), 15% (26), 
21% (30), 33% (38), and 37% (29). The most reliable assessment 
probably is a recently published meta-analysis covering 14 studies, 
estimating 20% of ADPKD children having hypertension (39).
The pathogenesis of hypertension in ADPKD includes a 
complex and multifactorial process, involving the renin–angio-
tensin–aldosterone system (RAAS), the sympathetic nervous 
system, sodium retention, and endothelial dysfunction. First, the 
presence of growing renal cysts was shown to attenuate intrarenal 
blood vessels, suggesting the presence of local renal ischemia 
and hypoxia. This in turn suggests stimulation of the RAAS in 
ADPKD. Both increased circulating (40) as intrarenal (41) RAAS 
activity was demonstrated in patients with ADPKD. Second, it 
is known that RAAS activation stimulates the sympathetic nerv-
ous system and vice  versa. Indeed, adult hypertensive ADPKD 
patients have significantly higher plasma catecholamine concen-
trations compared to patients with essential hypertension (42). 
Third, sodium retention plays a role. Interestingly, adult patients 
with normotension were shown to exhibit an increased total body 
sodium as compared with their unaffected siblings, suggesting 
an early role of RAAS (43). Last, expression of Pkd1 and Pkd2 
was shown in the major vessels and in the cilia of endothelial 
and vascular smooth muscle cells. Decreased or absent PC1 or 
-2 levels are associated with abnormal vascular structure and 
function, via reduced nitric oxide (NO) levels due to diminished 
Ca2+-dependent endothelial NO syntheses activity, resulting in 
an altered endothelial response to shear stress with attenuation 
in vascular relaxation. Moreover, decreased NO production 
leads to the activation of the RAAS, next to its triggering by cyst 
enlargement and intra-renal ischemia (44). However, it is still 
unclear which factor hypertension in ADPKD is mainly due 
to. The early onset of hypertension in ADPKD, probably still 
underdetected and therefore left untreated, is associated with left 
ventricular hypertrophy (LVH) in half of the patients in their 40s 
(45). Importantly, cardiovascular complications appear to be the 
leading cause of death in patients with ADPKD. Therefore, LVH 
should be prevented in patients with ADPKD, as it is known to be 
associated with coronary heart disease, cardiac failure, arrhyth-
mias, and sudden death (46).
A correlation between TKV and cyst volume, and hyper-
tension was observed in a longitudinal MRI study in ADPKD 
children: the hypertensive subgroup had a larger increase in both 
cyst volume and number than the normotensive (47). Also, the 
prevalence of hypertension was found to be significantly higher 
in children with a decreased urinary concentrating capacity com-
pared to those with a normal concentrating capacity. Significant 
negative correlations were shown between urinary concentrating 
capacity, blood pressure and the number of renal cysts (24).
Vascular dysfunction begins early in the course of ADPKD. 
In normotensive patients with preserved renal function, the 
endothelium-dependent dilatation and arterial stiffness were 
evaluated and compared to age and sex matched healthy con-
trols, by measuring the brachial artery flow-mediated dilation 
(FMDBA) and the carotid-femoral pulse wave velocity (CFPWV), 
respectively. FMDBA was lower in 25% of patients, indicating an 
impaired endothelium-dependent dilatation, while CFPWV was 
higher in 14% of patients, designating increased arterial stiffness. 
Both are well-known independent predictors of future cardiovas-
cular comorbidity and mortality (48).
Another possible cardiovascular feature in ADPKD, is mitral 
valve prolapse, occurring in 12% of children (15). Next, the 
association of ADPKD with intracranial aneurysm formation is 
well known (49). Almost all cases of ruptured intracranial aneu-
rysms occur in adult patients with a median age at rupture of 
40 years. In a study screening ADPKD patients, aged 7–87 years, 
the prevalence of intracranial aneurysm was 12.4%, reaching a 
peak in the 60–69 years age group; and higher in patients with 
a positive family history of hemorrhagic stroke or intracranial 
aneurysm. Only 1 patient had an aneurysm before the age of 
29 years, but the authors do not state the exact age of this patient 
(49). However, case reports describe rupture at very young ages, 
even neonatal (50, 51). Although rare, this complication might be 
lethal in young patients.
extrarenal Manifestations in Childhood: 
Others
Recently, evidence has emerged showing bone involvement in 
ADPKD (7–14). Indeed, PC1 is highly expressed in both osteo-
blasts and osteocytes and a homozygous PKD1 null mutation 
in mice was shown to cause polyhydramnios, hydrops fetalis, 
spina bifida, and osteochondrodysplasia (52, 53). Moreover, the 
PC1 C terminal tail regulates TAZ expression, an enhancer of 
RUNX2-mediated osteoblast differentiation and suppressor of 
PPARγ-stimulated adipocyte differentiation. A causal relation-
ship between mutant PC1, decreased Runx2 levels, and impaired 
osteoblast differentiation leading to a defect skeletogenesis was 
described (9, 54).
It has been demonstrated that fibroblast growth factor 23 
(FGF23), a phosphaturic hormone secreted by osteocytes, 
was studied in different ADPKD rodent models. FGF23 levels 
were raised, but a peripheral biologic resistance to FGF23 was 
hypothesized to account for the absence of a renal phosphate leak 
or hypophosphatemia. Importantly, FGF23 was detected in cells 
lining renal cysts, from a rodent model (7). In ADPKD adults in 
chronic kidney disease (CKD) stages 1–2, FGF23 levels were highly 
increased compared to both healthy controls and CKD matched 
controls. However, the majority of the ADPKD population dis-
played FGF23 resistance, given the absence of a phosphaturic phe-
notype, confirming the observations from the animal models. This 
was hypothesized to be due to the deficiency of the FGF coreceptor, 
namely serum Klotho (sKlotho) (13). FGF23 has also been studied 
in ADPKD children with preserved renal function. Compared to 
healthy controls, patients had significantly lower serum phosphate 
SDS. In a quarter of the patient population, this was accompanied 
by low TmP/GFR levels for age, based on the reference values (55). 
Although FGF23 levels were similar in both groups, it is inappropri-
ately normal for the ADPKD cohort, given the hypophosphatemia 
in the latter. Also sKlotho levels were similar between both groups. 
Apart from the phenotypic differences in adulthood vs. childhood 
concerning FGF23 and phosphate metabolism, these anomalies 
seem to be ADPDK specific, as markedly FGF23 elevation is only 
found in non-ADPKD patients with advanced CKD stage, where 
it is thought to counteract phosphate retention and is classically 
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accompanied by an increased parathyroid hormone and decreased 
1,25-dihydroxyvitamin D levels (14). Moreover, given the observa-
tions in the pediatric cohort, it is an early disease phenomenon.
In the same pediatric ADPKD cohort, significantly lower values 
of bone alkaline phosphatase were seen compared to healthy controls 
(10). Based on these data and the findings from a bone biopsy study 
in which a low bone turnover was observed in young adult ADPKD 
patients with preserved kidney function (56), bone formation sup-
pression is hypothesized in ADPKD.
Also sclerostin, known to inhibit the osteo-anabolic Wnt/β-
catenin pathway, is an emerging player in the mineral metabolism 
phenotype of ADPKD. Higher osseous sclerostin expression has 
been reported in jck mouse model (57) and in a small cohort of 
adult ADPKD patients in ESRD (11). However, it could not be 
confirmed in a pediatric ADPKD cohort (10). This discrepancy 
remains to be elucidated, next to the clinical relevance of scle-
rostin overactivity in ADPKD, if confirmed in future studies.
In general, one of the main extrarenal manifestations of 
ADPKD is polycystic liver disease (PLD). In contrast to renal 
cyst formation, liver cyst formation does not affect liver function, 
although it can cause symptoms related to its mass effect when 
significant liver enlargement has occurred, or due to cyst bleeding 
or infection (58). In children, liver cyst formation is very rare 
(59). PLD is the result of ductal plate—the primitive biliary struc-
ture—malformations. Normally, ductal plate remodeling takes 
place from 12 weeks gestational age, up to term, but with a slow-
ing down between the 20th and the 32nd week of gestation (60). 
Ductal plate malformation leads to a partial to complete arrest 
of ductal plate remodeling, and therefore a persistent excess of 
embryonic biliary structures (61). Typically, these structures are 
present from a very early disease stage, but remain asymptomatic 
until cyst growth initiates in adulthood (62).
DiAGNOSiNG ADPKD iN CHiLDReN
The diagnosis of ADPKD in children can be made either unin-
tentionally or actively, via screening. First, children at-risk for 
ADPKD might present with symptoms such as urinary tract 
infection(s), hematuria, enuresis etcetera, leading to their diag-
nosis when further investigated. Children might be diagnosed 
unintentionally as well, starting from the routinely performed 
prenatal US during pregnancy. Prenatally, the typical—although 
not specific for ADPKD—sonographic characteristics are mod-
erately enlarged hyperechogenic kidneys with an increased corti-
comedullary differentiation (CMD). Other prenatal sonographic 
features such as an absent or decreased CMD and cortical cysts 
are less frequently seen (21). Although a prenatal presentation of 
ADPKD is rare, this form is recurrent within families, suggest-
ing a common genetic modifying background with low levels of 
PC1 function (63) or the association with other modifying genes 
such as HNF1B or PKHD1 (64). In other cases, children might 
be diagnosed unintentionally postnatally, after the coincidental 
detection of renal cysts on an abdominal US performed for 
other reasons, most frequently abdominal pain. Second, active 
presymptomatic testing might be requested by the parents and/or 
the adolescents themselves. However, the diagnosis of ADPKD, 
especially its timing, represents controversies that we will discuss 
later in this review.
We first aim to demonstrate the challenges and limitations in 
the methods for the diagnosis of ADPKD in children and the 
lack of definite criteria for individuals under the age of 15 years. 
Indeed, presymptomatic testing in children at-risk for ADPKD, 
due to their positive familial history, can be executed by clinical 
evaluation and/or imaging. However, genetic evaluation is needed 
to resolve some cases. Most diagnoses of ADPKD are established 
on a positive family history combined with imaging [sonographic 
(65, 66) or MRI (67)] findings. However, for individuals under the 
age of 15 years, there are no validated diagnostic imaging criteria 
available (36, 68). As simple renal cysts occur rarely in childhood 
(69), a child with a positive family history for ADPKD, having a 
single cyst, preferably > 1 cm in diameter, is generally assumed 
to have the diagnosis of ADPKD, although this was never fully 
evaluated and validated. Moreover, based on renal US findings, 
one can only exclude disease presence in at-risk individuals aged 
30–40 years or older (65–67). Based on MRI, this will probably 
be possible at an earlier age, but a cutoff age for a definite exclu-
sion is not set yet. In case of a negative US and the patient and 
their family are willing to have a more definitive evaluation, gene 
sequencing of the PKD genes can be performed. However, this is 
not yet routinely used in clinical practice yet due to its high cost 
and challenging analysis. These are explained by the presence of 
six PKD1 pseudogenes and the remarkable allelic heterogeneity. 
While the diagnostic accuracy of PKD1 and PKD2 gene mutation 
testing was found to be lower than the accuracy of US examina-
tion in adults above the age of 30  years, the relative accuracy 
of genetic vs. sonographic testing was comparable for children 
younger than 15 years in PKD1 and superior in PKD2 individuals 
(65). Also, in case the familial mutation has been identified, it is 
more cost effective to sequence the exon with the known muta-
tion in at-risk individuals of this specific family. However, in that 
case, there is still a chance of a non-familial de novo mutation, not 
completely excluding the disease. Also, in case of a non PKD1 non 
PKD2 family, in which there is a clear ADPKD family history, but 
the PKD gene mutational analysis remains negative, exclusion of 
the disease in at-risk individuals will be possible only by means of 
a negative renal US at the age of 30–40 years or older (70).
Importantly, children who were diagnosed in utero or within 
their first 18 months of life, the so-called VEO group, represent 
a particularly high-risk group of ADPKD patients and should be 
managed accordingly. Indeed, this group was shown to have more 
hypertension and progression of eGFR < 90 mL/min/1.73 m2 by 
the last follow-up at the median age of 16 years; although they 
had similar rates of glomerular hyperfiltration compared to a 
non-VEO ADPKD control group (27).
THe CONTROveRSY OF TeSTiNG  
AT-RiSK CHiLDReN FOR THe PReSeNCe 
OF ADPKD
Currently, apart from the Kidney Disease: Improving Global 
Outcomes (KDIGO) Controversies Conference Report (71) and 
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the European ADPKD Forum (EAF) Report (72), no guidelines 
are available for the clinical care of ADPKD families.
In the KDIGO consensus, it is recommended to have at-
risk children screened for hypertension, starting at the age of 
5  years, and repeated every 3  years in case of normotension. 
Presymptomatic screening of ADPKD by means of US or genetic 
analysis is not currently recommended for at-risk children, 
while it is accepted for at-risk adults, in whom the potential 
benefits of presymptomatic diagnosis usually outweigh the risks. 
However, on the other hand, this consensus suggests the follow-
ing three options for at-risk children to be discussed thoroughly 
with their parents, so the parents can decide which approach 
will be taken. First, to screen the children and to disclose the 
results to the whole family; second to screen the children and 
disclose the results only to their parents, or last, not to screen 
the children. Moreover, according to the consensus, molecular 
genetic testing should be considered in cases of atypical renal 
imaging, discordant disease within a family; very mild PKD; 
in a patient without a family history for PKD; early and severe 
forms of PKD or PKD associated with syndromic features; and 
reproductive counseling (71).
In the EAF report, it is not discussed whether at risk children 
should be tested, although it is stated that genetic testing is vital 
for diagnosing ADPKD in children and that genetic counseling 
including informing the patients on the possibility of preimplan-
tation genetic diagnosis for ADPKD should be offered at initial 
diagnosis (72).
Taken together, it is still a matter of controversy whether asymp-
tomatic individuals at-risk for ADPKD, especially minors, should 
be tested for the presence of the disease or not (73). However, 
they and their family should be informed about the possibility 
of testing, and reasons why (not) to test. An important contra to 
testing, is the current absence of a cure (6). Although over the last 
decade, several drug targets based on the cellular mechanisms 
were tested in in vitro and in vivo models to slow down cystogen-
esis, only one drug demonstrated a moderate effect on disease 
progression in adult ADPKD patients, namely the vasopressin V2 
receptor antagonist tolvaptan (74), as also concluded by a recent 
Cochrane review on interventional studies in adult patients 
(75). Despite its adverse effects of polydipsia and polyuria, it is 
currently the only drug available in Europe, indicated in selected 
adult patients with CKD stages 1–3, having evidence of rapidly 
progressing disease (76). Important to take into account are the 
methodological issues, limiting the interpretation of results of the 
published trials up till now. Though these are often encourag-
ing, they are frequently restricted because of inadequate power, 
short study duration, patients’ heterogeneity (large differences in 
TKV and/or underlying mutation class for instance), doses with 
inadequate pharmacological effects and uncertain target organ 
concentration (77). Moreover, the question remains whether it 
would be more efficacious to start treatment before extensive 
renal damage has occurred. A second contra is the potential 
induction of psychological stress in an at-risk individual and his/
her family, possibly causing feelings of (survival) guilt; although 
not only the certainty of having a diagnosis might be experienced 
as unbearable, but also the uncertainty when not testing (78, 79). 
A recently published mono-center survey performed in adults 
diagnosed with ADPKD, prior to the start of renal replacement 
therapy, showed that 22% had a clinically significant depression 
and 62% felt guilty about passing the disease on to their children. 
The latter represented one of the major psychological challenges 
confronting patients with ADPKD (80). A third argument against 
presymptomatic testing is the negative financial consequences a 
diagnosis with ADPKD might cause, such as difficulties obtaining 
insurances (81).
On the other hand however, presymptomatic testing not only 
has a prognostic value, by means of TKV measurement and 
PKD genotyping; it may also give caregivers the opportunity 
to target modifiable risk factors for disease progression from 
an early disease stage (82), thereby improving long-term renal 
outcome (71). This is supported by the observation of similar 
outcomes in a study comparing the presence of nephromegaly, 
hypertension, microalbuminuria and decreased eGFR between 
a cohort in which diagnosis was based on postnatal US screen-
ing vs. after presenting symptoms (26). This emphasizes the 
importance of regular screening for hypertension and pro-
teinuria in at-risk children, but could also be seen as supporting 
argument for presymptomatic testing. Indeed, the significance 
of early treatment of disease symptoms should not be neglected. 
In children, this was demonstrated by slower cyst growth in 
ADPKD children with normotension compared to those with 
hypertension (47). Moreover, effective blood pressure control 
from childhood on may ameliorate the cardiovascular outcomes 
in these patients, known to be at high risk for early cardiovas-
cular events (83, 84). Although glomerular hyperfiltration was 
shown to correlate with a more severe renal phenotype (29), 
there is no evidence (yet) for regular screening and/or treat-
ment of it. Also, for some identified disease progression mark-
ers in adults, it remains to be determined to what extent their 
modification may influence the clinical course of ADPKD, such 
as for higher urinary sodium excretion and lower serum HDL 
cholesterol (85). A benefit accruing to all tested individuals, is 
their empowerment, namely the process through which people 
gain greater control over decisions and actions affecting their 
health and life, an important aspect is informed reproductive 
decision making (79).
A survey performed among European pediatric and adult 
nephrologist and geneticists before the KDIGO publication 
and the EMA approval of tolvaptan, demonstrated that their 
clinical practice and beliefs are very heterogeneous regarding 
testing of asymptomatic offspring and other ethical issues in the 
management of ADPKD families (86). In this study, agreement 
between respondents was observed regarding clinical testing of 
at-risk minors, although pediatric nephrologists supported this 
significantly stronger compared to geneticists. Also, the three 
groups of caregivers showed a moderate disagreement on the 
performance of genetic testing for ADPKD in at-risk minors. 
However, the differences observed in their counseling attitude 
were only attributable to their professional discipline. Therefore, 
ADPKD patients and their family tend to receive conflicting and/
or incomplete information from their caregivers. As suggested in 
the article, a reevaluation in a few years from now, to evaluate how 
the KDIGO consensus statement and the availability of tolvaptan 
and probably other upcoming treatment options influence both 
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professionals and patients beliefs on these issues, would be inter-
esting to perform (86).
CHiLDHOOD AS A CRiTiCAL 
THeRAPeUTiC wiNDOw FOR (FUTURe) 
THeRAPieS
As suggested earlier, we should ask ourselves whether the best 
chance for preserving long term renal function in ADPKD is to 
take an early start. Starting prevention before extensive renal dam-
age has occurred, thus at a young(er) age, might indeed improve 
the long term renal survival. Moreover, as suggested by Grantham 
et al., based on the assumption that decline in GFR is linked to the 
progressive increase in TKV, early treatment has the potential to 
delay renal dysfunction progression by more than a decade. When 
therapy is started at 18 years of age, reduction in the rate of TKV 
growth is predicted to shift from 5 to 2.5%, or 1.25% per year—a 
change that yields a vastly different effect on GFR decline than 
that induced by starting therapy later in life (87).
However, before heading toward cystogenesis inhibiting 
treatment options in children, disease manifestations requir-
ing symptomatic treatment should be identified and managed 
adequately (16).
In both children and adults with ADPKD, hypertension is a 
predictor of worse renal outcome. Moreover, it is associated with 
increased cardiovascular morbidity and mortality (15).
In adults with ADPKD, LVH, a major cardiovascular risk factor, 
was significantly further decreased by rigorous (<120/80 mmHg) 
than standard blood pressure control (<140/90 mmHg), although 
this was not associated with a statistically significant difference in 
renal function between the two treatment arms (88). Moreover, 
from the HALT/PKD study, it was shown in an early ADPKD 
cohort that as compared with standard blood pressure control 
(120/70 to 130/80  mmHg), rigorous blood-pressure control 
(95/60 to 110/75 mmHg) was associated with a slower increase 
in TKV, no overall change in the eGFR, a greater decline in left 
ventricular mass index, and a greater reduction in albuminuria 
levels (89). These data may be particularly applicable to children 
as the study cohort represented early stages of ADPKD. However, 
a study using angiotensin converting enzyme inhibitors (ACEi) 
in children and young adolescents with ADPKD, over a period of 
5 years, failed to demonstrate a significant effect on renal growth 
in the total cohort. Importantly, ACEi treatment was associated 
with stable renal function and left ventricular mass index in the 
(borderline) hypertensive children, who are at particular risk 
for increases in renal volume and left ventricular mass index 
and decreased renal function as compared with the other study 
groups (90).
KDIGO states that treatment of hypertension in pediatric 
ADPKD patients should follow prevailing pediatric guidelines; 
meaning a goal blood pressure below the 90th percentile for age, 
sex, and height; with the only exception that RAAS blockade is 
preferred as first-line treatment (71). However, given these find-
ings, it was recommended recently to use an ACEi with a target 
blood pressure of <110/75 in young adults older than 18 years; 
and in adolescents and children with borderline hypertension 
(75–95th percentile) or hypertension (≥95th percentile), to 
use an ACEi to achieve a goal blood pressure ≤50th percentile. 
Angiotensin receptor blockers (ARBs) can be used in patients 
who do not tolerate ACEi (15). Combination of both RAAS 
blockers should be avoided as no benefit was demonstrated by 
adding an ARB (telmisartin) to an ACEi (lisinopril) on ADPKD 
progression in adult patients with early or moderately advanced 
kidney disease (89). Moreover, girls of childbearing potential and 
their families should be informed on fetal toxicity of ACEi and 
ARBs (15).
Next, in a 3–year, phase III clinical trial of pravastatin on TKV 
and left ventricular mass index, pravastatin was effective in slow-
ing the progression of structural kidney disease in older children 
and young adults with ADPKD. There was no beneficial effect 
on the left ventricular mass index, nor on their urinary micro 
albumin excretion (91). However, a recently published post hoc 
analysis of the HALT PKD trials, comparing the outcomes of 
participants who never used statins with those who used statin 
for at least 3 years, failed to demonstrate a benefit of statin therapy 
in both subjects with a preserved renal function (Study A) as a 
reduced renal function (Study B) (92). Conclusions remain pre-
liminary, as the first study consisted of a relatively small cohort, 
and the post hoc analysis of the HALT PKD is limited given the 
small number of statin users in Study A, different statin drugs and 
doses used, non-randomized allocation and advanced disease 
stage in Study B. Also, as with ACEi, potential risks to the fetus 
with statin exposure during pregnancy should be reviewed prior 
to treatment to females of appropriate pubertal development.
As mentioned before, currently, the only drug available for 
selected (<50 years, CKD stages 1-3a, rapidly progressing dis-
ease) adult patients in Europe (76) is the vasopressin V2 recep-
tor antagonist tolvaptan. Tested in the TEMPO clinical trials, 
including adult patients with a relatively advanced disease stage 
(TKV >  750 mL), tolvaptan use was demonstrated to induce 
both a slower annual increase in TKV and a slower annual 
decline in kidney function in treated patients vs. controls (74). 
Despite its possible adverse effects—polydipsia, polyuria and 
significant liver enzyme elevation—tolvaptan is currently stud-
ied in a phase III double-blind placebo controlled clinical trial 
in a pediatric ADPKD cohort within Europe (NCT02442674) 
(93). Apart from this, there is one case report, describing the 
off-label use of tolvaptan in a severely affected neonate with 
ADPKD (94). Other coming exciting therapies, such as the 
AMPK activator metformin, are currently tested in adult 
patients, and will be tested in pediatric ADPKD depending on 
the results in adults (95). A general remark on (future) stud-
ies including children with ADPKD is that the subjects often 
are performed in tertiary and specialist centers. This might 
reflect highly selected populations, likely to contain a higher 
proportion of symptomatic children and “fast-progressors,” 
influencing the results.
CHALLeNGeS AND UNMeT NeeDS iN 
PeDiATRiC ADPKD CARe
In the care of pediatric ADPKD and their families, there is a clear 
need of a more standardized management. Few initiatives have 
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been taken so far, namely the KDIGO consensus and EAF report, 
however, conflicting recommendations still need standardiza-
tion and completion such as testing of at-risk minors and the 
target blood pressure when treating hypertension (50th vs. 90th 
percentile) as discussed earlier. Moreover, there are no details 
provided on how blood pressure should be monitored, namely 
via an office blood pressure measurement or a 24-h ambulatory 
blood pressure monitoring. There is evidence that the latter 
should be performed routinely from a large pediatric cohort, in 
which 51.9% of patients lacked a physiological nocturnal blood 
pressure dipping and 18.2% had isolated nocturnal hypertension 
(Massella L et al. High prevalence of hypertension in a European 
cohort of children with ADPKD: results of the ADPKiDs study. 
IPNA; 2016; Iguacu, Brazil) (96).
Others recommendations are absent, such as on screening for 
intracranial aneurysms, both in adults and in children, a topic in 
which many areas of uncertainty remain, as observed in a recent 
survey among European French speaking nephrologists (97). 
However, there is recent evidence that systematic screening in all 
ADPKD patients, regardless of the family history for intracranial 
aneurysms, is cost-effective (98). Moreover, despite the recom-
mendations, it will take time to implement these. Till now, many 
at risk children with ADPKD are not under regular follow-up and 
remain undiagnosed (39). Thus, leaving the important issue who 
should be responsible for informing them in adulthood: only the 
family, both the family and the caregivers or only the caregivers? 
From the caregivers’ point of view, this is a shared responsibil-
ity for professionals with the family (86), although it would be 
interesting to know the opinion of ADPKD patients on this.
Next, there is a need of diagnostic imaging criteria under the 
age of 15  years apart from the currently used eminence-based 
guidelines. The most important is the need for clear prognostic 
criteria from childhood, as a validated method to identify slow vs. 
rapid progressors does not exist in the pediatric population, except 
in case of VEO ADPKD (27). However, this is necessary for the 
stratification of young patients in clinical trials, and possibly as 
new and better outcome measures. Indeed, TKV as a prognostic 
marker is well-assessed and accepted, but only in studies starting 
to include patients from the age of 15 years (87). Moreover, TKV 
measurements via MRI were shown to be more accurate and 
reproducible compared to US in adults (99), however, unfeasible 
in many young children due to the need of sedation or general 
anesthesia. Therefore, new modalities should be tested for TKV 
measurement in ADPKD children. One promising option is a 
three dimensional US technique, which was shown a valuable 
alternative to MRI to measure, although underestimating MRI 
TKV (96, 100).
Untill now, most studies published were performed on small 
pediatric cohorts, while we need to build large cohorts before 
we will be able to define evidence-based recommendation for 
children with ADPKD. Therefore, we recently have launched 
our initiative of the “ADPedKD” international registry to collect 
retrospective and prospective longitudinal clinical, imaging, and 
genetic data of children until the age of 19 years.
CONCLUSiON
In conclusion, children and young adults with ADPKD may 
represent a critical therapeutic window to reduce future renal and 
cardiovascular risk. However, we are still far from standardized 
care for this population. Moreover, the ultimate goal should be to 
empower patients to make their own informed decisions.
According to the KDIGO consensus, the advised follow-up 
of at-risk children should encompass regular monitoring for 
disease manifestations such as hypertension and proteinuria, so 
treatment of these disease modifying factors is initiated as early 
as possible.
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